Diagnostic value of the novel CMR parameter "myocardial transit-time" (MyoTT) for the assessment of microvascular changes in cardiac amyloidosis and hypertrophic cardiomyopathy.

Grigorios ChatzantonisMichael BietenbeckAnca FlorianClaudia MeierPhilipp StallingDennis KorthalsHolger ReineckeAli Yilmaz

Published in: Clinical research in cardiology : official journal of the German Cardiac Society (2020)

The relative severity of CMD (measured by MyoTT) in relationship to extracellular changes (measured by native T1 and/or ECV) is more pronounced in HCM compared to CA-in spite of a higher absolute MyoTT value in CA patients. Hence, MyoTT may improve our understanding of the interplay between extracellular/intracellular and intravasal changes that occur in the myocardium during the disease course of different cardiomyopathies.

Keyphrases

hypertrophic cardiomyopathy
left ventricular
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
protein kinase
patient reported outcomes